DSM Pharmaceutical Products and Agennix AG have signed a new contract under which DSM will continue to provide commercial manufacture of talactoferrin for Agennix. DSM is currently manufacturing talactoferrin for ongoing clinical trials and will continue to supply clinical trials as well as a potential commercial launch. Under the contract, DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI) talactoferrin at commercial levels in anticipation of positive Phase III results ...